ATE223435T1 - Verfahren zur diagnose von störungen durch bestimmung der expression von gage- tumorabstossungsantigen-vorläufern - Google Patents

Verfahren zur diagnose von störungen durch bestimmung der expression von gage- tumorabstossungsantigen-vorläufern

Info

Publication number
ATE223435T1
ATE223435T1 AT94923463T AT94923463T ATE223435T1 AT E223435 T1 ATE223435 T1 AT E223435T1 AT 94923463 T AT94923463 T AT 94923463T AT 94923463 T AT94923463 T AT 94923463T AT E223435 T1 ATE223435 T1 AT E223435T1
Authority
AT
Austria
Prior art keywords
tumor rejection
rejection antigen
antigen precursors
expression
determining
Prior art date
Application number
AT94923463T
Other languages
English (en)
Inventor
Den Eynde Benoit Van
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE223435T1 publication Critical patent/ATE223435T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AT94923463T 1993-07-22 1994-07-13 Verfahren zur diagnose von störungen durch bestimmung der expression von gage- tumorabstossungsantigen-vorläufern ATE223435T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9603993A 1993-07-22 1993-07-22
US08/250,162 US5610013A (en) 1993-07-22 1994-05-27 Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
PCT/US1994/007878 WO1995003422A1 (en) 1993-07-22 1994-07-13 Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors

Publications (1)

Publication Number Publication Date
ATE223435T1 true ATE223435T1 (de) 2002-09-15

Family

ID=22254881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94923463T ATE223435T1 (de) 1993-07-22 1994-07-13 Verfahren zur diagnose von störungen durch bestimmung der expression von gage- tumorabstossungsantigen-vorläufern

Country Status (14)

Country Link
US (1) US5610013A (de)
EP (1) EP0711355B1 (de)
JP (1) JP3641692B2 (de)
KR (1) KR100281178B1 (de)
CN (1) CN1059465C (de)
AT (1) ATE223435T1 (de)
AU (1) AU677687B2 (de)
CA (1) CA2167692C (de)
DE (1) DE69431301T2 (de)
FI (1) FI960268A0 (de)
NO (1) NO960158L (de)
NZ (1) NZ269435A (de)
TW (1) TW498104B (de)
WO (1) WO1995003422A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648226A (en) * 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US6939707B2 (en) * 1993-07-22 2005-09-06 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode GAGE genes and uses thereof
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
EP0910646A1 (de) * 1996-06-25 1999-04-28 The Ludwig Institute for Cancer Research Glykogen phopshorylase krebsantigen aus dem gehirn
DK0970206T3 (da) 1997-01-27 2008-10-13 Ludwig Inst Cancer Res Lage-1-tumorassocierede nukleinsyrer
US5879892A (en) 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
AU3587599A (en) * 1997-11-28 1999-06-16 Invitrogen Corporation Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
US5905145A (en) * 1998-03-06 1999-05-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode TAGE molecules, and uses thereof
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6245525B1 (en) 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
AU3753499A (en) * 1998-04-20 1999-11-08 Paul B. Fisher Colon cancer-associated antigens and their diagnostic and therapeutic uses
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6509172B1 (en) 1998-09-30 2003-01-21 Ludwig Institute For Cancer Research Isolated, truncated nucleic acid which are members of the gage, and uses thereof
KR20020047249A (ko) 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
EP1259545A2 (de) * 2000-01-21 2002-11-27 Ludwig Institute For Cancer Research Mit dem "nicht-kleine-zellen" lungenkrebs assoziierte antigene und deren verwendung
EP1605045A3 (de) * 2000-02-15 2006-03-01 Curagen Corporation Polypeptide und dafür kodierende Nukleinsäure
WO2001061009A2 (en) * 2000-02-15 2001-08-23 Curagen Corporation Polypeptides and nucleic acids encoding same
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
US20040180354A1 (en) * 2002-09-06 2004-09-16 Simard John J.L. Epitope sequences
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
EP1633387B1 (de) * 2003-06-17 2012-02-22 Mannkind Corporation Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
KR101076578B1 (ko) 2004-06-23 2011-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 2입자 착물을 이용한 생물학적 분자의 검출을 위한 방법 및조성물
CA2592968A1 (en) 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
ES2413079T3 (es) 2005-06-17 2013-07-15 Mannkind Corporation Métodos y composiciones para desencadenar respuestas inmunitarias multivalentes contra epítopos dominantes y subdominantes expresados en células cancerosas y estroma tumoral
CN102905534B (zh) * 2010-04-06 2016-03-02 埃克瑟赛特医疗私人有限公司 治疗癌症的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105538A (en) * 1977-01-21 1978-08-08 Mattox William J Process for the refining of used motor oils and products thereof
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen

Also Published As

Publication number Publication date
JPH09504165A (ja) 1997-04-28
CN1059465C (zh) 2000-12-13
NZ269435A (en) 1997-11-24
KR100281178B1 (ko) 2001-04-02
NO960158L (no) 1996-01-22
US5610013A (en) 1997-03-11
CA2167692A1 (en) 1995-02-02
DE69431301D1 (de) 2002-10-10
CA2167692C (en) 2009-07-07
WO1995003422A1 (en) 1995-02-02
NO960158D0 (no) 1996-01-15
EP0711355A1 (de) 1996-05-15
CN1127532A (zh) 1996-07-24
AU677687B2 (en) 1997-05-01
AU7332294A (en) 1995-02-20
JP3641692B2 (ja) 2005-04-27
EP0711355B1 (de) 2002-09-04
DE69431301T2 (de) 2003-07-31
FI960268A7 (fi) 1996-01-19
FI960268L (fi) 1996-01-19
EP0711355A4 (de) 1998-05-06
TW498104B (en) 2002-08-11
FI960268A0 (fi) 1996-01-19

Similar Documents

Publication Publication Date Title
DE69431301D1 (de) Verfahren zur diagnose von störungen durch bestimmung der expression von gage-tumorabstossungsantigen-vorläufern
DE69531866D1 (de) Isoliertes nukleinsäuremolekül, das für den tumorabstossungs-antigenvorläufer dage kodiert und seine verwendung
EP0711173A4 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
ATE338818T1 (de) Verfahren zur diagnose des glaukoms
DE69617440D1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DE69020376D1 (de) Verfahren zur Herstellung von Mono- oder Dicarbonsäure-Stoffen, die durch langkettige Kohlenwasserstoffe substituiert sind.
DE60041818D1 (de) Gereinigtes antigen für die alzheimer krankheit und verfahren zu dessen herstellung und verwendung
DE3866558D1 (de) Verfahren zur herstellung von 1,1,1-trifluor-2,2-dichloraethan durch hydrofluorierung in gegenwart von katalysatoren.
ATE258379T1 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
EP1361229A3 (de) Verwendung von Tyrosine Kinase (PYK2) zur Produktion von Antikörper
ATE234858T1 (de) Isolierte und verkürzte nukleinsäuremoleküle kodierend für gage-tumorabstossungsantigen
ATE245699T1 (de) Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
ATE39249T1 (de) Verfahren zur herstellung von polyisocyanatopolyisocyanuraten durch katalytische cyclotrimerisierung von polyisocyanaten.
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
DE3681033D1 (de) Katalytisches verfahren zur herstellung von fluoraomatischen verbindungen mittels n-sek-alkylpyridiniumsalze.
ATE127478T1 (de) Onkogen kodierendes polypeptid, das wachstumsfaktoraktivität besitzt, verfahren zu seiner herstellung und verwendung.
DE69032526D1 (de) cDNS-FRAGMENT, DAS FÜR EIN INTERFERON-ALPHA-REZEPTOR-GEN KODIERT UND VERFAHREN ZUR HERSTELLUNG EINES ENTSPRECHENDEN PROTEINS
DE3777596D1 (de) Verfahren zur herstellung von 2-nitro-5-phenoxy-n-alkylsulfonylbenzamiden durch nitrierung.
DE69521281D1 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
PT914417E (pt) Dnase ii humana
DE58904746D1 (de) Antikoerper, verfahren zu ihrer herstellung, klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren.
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
ATE90793T1 (de) Antikoerper, verfahren zu ihrer herstellung, klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties